Amy E. McKee, who serves as a director at BioCryst Pharmaceuticals Inc. (BCRX), recently completed a sale of company shares. On May 18, 2026, Ms. McKee sold a total of 11,180 common shares of the firm's stock, amounting to $100,284.
The details of this transaction indicate that the shares were divested at a weighted average price of $8.97 per share. Furthermore, individual sale prices for these units ranged between $8.96 and $8.985. Following the completion of this sale, Ms. McKee's direct holdings in BioCryst Pharmaceuticals common stock were reported to stand at 31,252 shares.
This insider selling activity is noted against a backdrop of recent market performance for BioCryst. The company's shares have seen an appreciation of 29% over the preceding six months. Complementing this analysis, one financial evaluation indicated that the stock might be undervalued at current trading levels, assigning the company a 'GREAT' financial health score.
The recent insider activity must also be viewed in light of BioCryst Pharmaceuticals’ Q1 2026 earnings announcement, which presented a varied picture of the company's operational and financial standing. The reported figures revealed notable differences between actual results and market expectations for key metrics.
Specifically regarding profitability, the company disclosed an Earnings Per Share (EPS) of -2.98. This figure represented a substantial deviation from the forecast of 0.05, resulting in a calculated surprise percentage of -6060%. Conversely, when examining revenue generation, BioCryst Pharmaceuticals managed to surpass market predictions. The firm reported total revenues of $156.41 million, exceeding the anticipated benchmark of $151.66 million. This achievement represents an increase of 3.13% over expected revenue.
These contrasting results underscore a period of mixed financial performance for BioCryst during the first quarter. While the growth in revenue figures could be considered encouraging by some observers, the significant miss on EPS presents a distinct challenge to the company's immediate financial narrative. As of now, analyst firms have not yet issued any formal upgrades or downgrades following the release of these earnings reports. These recent developments provide critical insights into both the firm’s current market valuation and its underlying operational health.
Key Observations for Investors
- The reported EPS of -2.98 significantly missed the forecasted 0.05, representing a substantial negative surprise.
- Despite revenue growth, the overall financial picture remains mixed due to the sharp discrepancy in earnings per share (EPS).